Entity

Time filter

Source Type

Woburn, MA, United States

Patent
Jasco Pharmaceuticals LLC | Date: 2012-04-20

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2012-10-24

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2011-02-17

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), the TGF pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), the TGF pathway and/or the Wnt pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2014-12-19

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK11, CK12, CK13, CK2, Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.


Patent
Jasco Pharmaceuticals LLC | Date: 2010-12-23

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Discover hidden collaborations